---
title: "688513.SH (688513.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688513.SH/news.md"
symbol: "688513.SH"
name: "688513.SH"
parent: "https://longbridge.com/en/quote/688513.SH.md"
datetime: "2026-05-20T03:43:24.313Z"
locales:
  - [en](https://longbridge.com/en/quote/688513.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688513.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688513.SH/news.md)
---

# 688513.SH (688513.SH) — Related News

### [EASTON BIOPHARMACEUTICALS: There are no matters that should have been disclosed but were not disclosed](https://longbridge.com/en/news/286895644.md)
*2026-05-19T10:34:37.000Z*
> EASTON BIOPHARMACEUTICALS issued a notice of unusual fluctuations, stating that the daily closing price of the company's

### [EASTON BIOPHARMACEUTICALS: Cancel the special account for raising funds for the industrialization project of innovative drugs for major diseases](https://longbridge.com/en/news/286752523.md)
*2026-05-18T10:11:13.000Z*
> EASTON BIOPHARMACEUTICALS announced that the company has canceled the special account for the "Innovative Drug Industria

### [EASTON BIOPHARMACEUTICALS: Application for listing permission of Class 2 modified new drug accepted](https://longbridge.com/en/news/286540615.md)
*2026-05-15T09:40:47.000Z*
> EASTON BIOPHARMACEUTICALS announced that the company recently received the "Acceptance Notice" for the marketing authori

### [EASTON BIOPHARMACEUTICALS: Class 2 modified new drug acetaminophen and oxycodone sustained-release tablets have obtained a drug registration certificate](https://longbridge.com/en/news/285364996.md)
*2026-05-06T11:17:03.000Z*
> EASTON BIOPHARMACEUTICALS recently obtained the Drug Registration Certificate for Oxycodone and Acetaminophen Extended-R

### [Net profit growth of nearly 20% highlights growth resilience; EASTON BIOPHARMACEUTICALS' innovative collaboration accumulates value depth](https://longbridge.com/en/news/283929618.md)
*2026-04-24T02:38:13.000Z*
> Under the background of policy adjustments in the pharmaceutical industry, EASTON BIOPHARMACEUTICALS achieved an operati

### [EASTON BIOPHARMACEUTICALS: Net profit in the first quarter of 2026 was 50.831 million yuan, a year-on-year decrease of 16.11%](https://longbridge.com/en/news/283491868.md)
*2026-04-21T11:37:52.000Z*
> EASTON BIOPHARMACEUTICALS announced that in the first quarter of 2026, the operating revenue was 326 million yuan, a yea

### [](https://longbridge.com/en/news/282445595.md)
*2026-04-12T12:21:11.000Z*
> This week's largest increase in margin financing balance: ANDAAS margin financing balance: 442 million yuan, balance inc

### [](https://longbridge.com/en/news/279355263.md)
*2026-03-17T02:28:07.000Z*
> Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reac

### [](https://longbridge.com/en/news/278483822.md)
*2026-03-10T03:15:17.000Z*
> The A-share innovative drug concept continues to strengthen, with Salubris hitting the daily limit, HITECK and WECOME ri